BeyondSpring Presents New Plinabulin Data At ESMO Congress

BeyondSpring Pharmaceuticals BYSI announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 2021 Congress.
Plinabulin combined with G-CSF to prevent CIN is currently under U.S. and China regulatory review with an FDA PDUFA date of November 30.
The data showed that the severe neutropenia endpoint is correlated with clinically meaningful endpoints in a meta-analysis with over 7000 patients.
Related Content: BeyondSpring Stock Is Up More than 300%: What You Need To Know?
The meta-analysis dataset included data from 36 published world literature in various cancers and chemotherapy and the plinabulin CIN program, including 105 and 106 CIN studies (n=496).
Correlations of exponential equations between the rate of febrile neutropenia, duration of severe neutropenia, and absolute neutrophil count nadir were statistically significant.
In the PROTECTIVE-2 Phase 3 trial, plinabulin/pegfilgrastim combo therapy had superior efficacy in preventing severe neutropenia versus pegfilgrastim alone (68% vs. 86%).
Patients receiving plinabulin and pegfilgrastim recovered to their pre-chemotherapy physical wellbeing levels more rapidly and experienced less deterioration.
Price Action: BYSI stock is down 1.65% at $22.59 during the market session on the last check Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)